Shares of Myriad Genetics ( MYGN) rose 14.6% to $21.40 in early trading on Wednesday. The Salt Lake City-based firm after the market close on Tuesday reported fiscal third quarter 2017 results that topped analysts' expectations.

Myriad reported adjusted earnings per share of $0.27 on revenue of $196.9 million. Analysts had forecast adjusted EPS of $0.23 on revenue of $189.1 million, according to FactSet Research Systems.

For fiscal year 2017, the company raised its revenue guidance to $763 million to $765 million from the previous range of $745 million to $755 million. Myriad narrowed its adjusted EPS guidance to $1.01 to $1.03 from the prior guidance of $1.00 to $1.05.

Shares of Spectrum Pharmaceuticals ( SPPI) were down 6.1% to $7.07. The Henderson, Nev.-based firm after the market close on Tuesday reported first-quarter non-GAAP net loss of $11.4 million, or $0.14 per basic and diluted share, compared with non-GAAP net income $0.3 million, or $0.01 per basic share and less than $0.01 per diluted share, in the same period in 2016. Revenue was $29.1 million, versus $43.87 million in the year-ago period.

Among the other biotech movers was Array BioPharma ( ARRY) , up 8.6% to $7.99.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments